A Delaware federal judge ruled on Oct. 13 that Actavis Laboratories FL Inc. infringed three patents with a planned generic version of the weight-loss drug Contrave, rejecting the company’s defense as a “classic case” of hindsight bias.
In a 35-page opinion, U.S. District Judge Richard G. Andrews of the District of Delaware said that Actavis had failed to invalidate Orexigen Therapeutics Inc.’s patents during a three-day trial in June.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]